ClinicalTrials.gg
RecruitingNCT07729462Updated Oct 14, 2026

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

A Phase 3 interventional study of Rimegepant and Placebo in Preventive Treatment of Migraine, sponsored by Pfizer. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 14, 2026First site in IsraelSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.

Planned enrollment
20th of 32
400 · median 618
Started
2026
with 5 others
Phase 3
14 of 32
5 open now
Primary completion
2028-10
later than 9 of 14 live
Registered
30th of 32
by date
Lead sponsor
24 of 32
Pfizer

Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 20th largest by planned enrollment, is one of 6 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 30th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About rimegepant

rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing rimegepant in Migraine Disorders, or all of them as a file.
02

Study summary

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine attacks in adults and for the preventive treatment of episodic migraine in adults when administered every other day. This study evaluates once daily rimegepant for the preventive treatment of chronic migraine.

After a 28-day observation period without study intervention, eligible participants will be randomized in a 1:1 ratio to receive either rimegepant 75 mg orally disintegrating tablet (ODT) or matching placebo once daily for 12 weeks under double-blind conditions. Participants who remain eligible at the end of the double-blind treatment phase will enter a 12-week open-label treatment period, during which all participants will receive open-label rimegepant 75 mg once daily. During this period, participants may also take an additional rimegepant tablet for the acute treatment of breakthrough migraine attacks, up to 10 doses per month. A 28-day follow-up period completes the approximately 32-week study.

The primary objective of the study is to determine whether once-daily rimegepant is more effective than placebo in reducing monthly migraine days relative to the observation period in adults with chronic migraine. Secondary objectives include evaluating differences between rimegepant and placebo in migraine responder rates, headache severity, acute migraine medication use, quality of life, work productivity, cognitive functioning, and safety and tolerability.

Approximately 400 adults aged 18 years or older with a diagnosis of chronic migraine for at least 1 year will be enrolled at multiple study sites.

Read the detailed description

This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of rimegepant 75 mg administered once daily for the preventive treatment of chronic migraine in adults. Approximately 400 participants with chronic migraine will complete a 28-day Observation Phase and then be randomized in a 1:1 ratio to receive either rimegepant 75 mg or placebo during a 12-week Double-Blind Treatment (DBT) Phase.

The primary objective is to determine whether once-daily rimegepant is superior to placebo in reducing monthly migraine days in adults with chronic migraine. Secondary objectives include evaluation of migraine responder rates, headache frequency and severity, acute migraine medication use, quality of life, headache-related disability, work productivity, cognitive functioning, and patient-reported improvement.

Participants will record migraine and headache information using an electronic diary and will complete protocol-specified efficacy and safety assessments throughout the study. Safety evaluations will include monitoring of adverse events, clinical laboratory assessments, vital signs, electrocardiograms, and other protocol-defined safety measures.

Eligible participants who complete the DBT Phase and remain eligible may enter a 12-week Open-Label Extension (OLE) Phase, during which all participants will receive open-label rimegepant 75 mg once daily. During the OLE Phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month. Following completion or discontinuation of study treatment, participants will enter a 28-day Follow-Up Phase.

The study is designed to determine whether once-daily rimegepant provides superior efficacy to placebo for the preventive treatment of chronic migraine in adults and to further characterize the safety and tolerability profile of daily rimegepant administration.

03

Conditions studied

  • Preventive Treatment of Migraine

Browse trials for

Keywords

  • Migraine Prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥18 years of age.
  • Diagnosis of chronic migraine, with or without aura, according to International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria.
  • History of migraine for at least 1 year before screening.
  • Migraine onset before 50 years of age and chronic migraine onset before 65 years of age.
  • Migraine attacks lasting 4 to 72 hours when untreated or unsuccessfully treated.
  • During the 3 months prior to screening, an average of:
  • ≥15 monthly headache days (MHDs),
  • including ≥8 monthly migraine days (MMDs),
  • and ≥1 non-headache day per month.
  • Completion of the Observation Phase and fulfillment of all protocol-defined eligibility requirements prior to randomization.
  • Willing and able to comply with study procedures, including completion of the electronic diary.

Exclusion criteria

Exclusion Criteria:

  • Prior use of rimegepant for migraine prevention.
  • History of treatment failure of:

    • 2 gepants, or
    • 2 CGRP-targeting biologics, or
    • 1 gepant and ≥1 CGRP-targeting biologic.
  • Failure of >4 migraine preventive medications, including at least 2 with different mechanisms of action.
  • Any medical or psychiatric condition, or laboratory abnormality, that in the investigator's judgment may increase risk to the participant or interfere with study participation or interpretation of results. This includes, but is not limited to, uncontrolled hypertension or a history of Raynaud's phenomenon.
  • Pregnant, breastfeeding, planning to become pregnant, or planning to initiate breastfeeding during the study.
  • Positive amphetamine screening result unless attributable to prescribed stimulant therapy that has been stable for at least 3 months prior to Visit 1 and is expected to remain stable throughout study participation.
  • Use of products or participation in another clinical study within protocol-defined exclusion windows.
  • Any other condition that, in the opinion of the investigator or sponsor, would make study participation unsafe or compromise study conduct.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Rimegepant 75 mg orally disintegrating tablet (ODT) once daily

    Participants will receive rimegepant 75 mg orally disintegrating tablet (ODT) once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.

    Drug: Rimegepant

  • Placebo comparator
    Matching placebo once daily for 12 weeks during the double-blind treatment phase

    Participants will receive matching placebo once daily during the 12-week double-blind treatment phase. Eligible participants may subsequently enter a 12-week open-label extension phase and receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough migraine attacks, up to 10 doses per month.

    Drug: Placebo

Interventions

  • Rimegepant 75 mg orally disintegrating tablet (ODT) administered once daily during the 12-week double-blind treatment phase. Participants who enter the 12-week open-label extension phase will receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough headache attacks, up to 10 doses per month.

  • DrugPlacebo

    Matching placebo orally disintegrating tablet administered once daily during the 12-week double-blind treatment phase. Participants who enter the 12-week open-label extension phase will receive open-label rimegepant 75 mg once daily. During the open-label extension phase, participants may also take an additional dose of rimegepant 75 mg for the acute treatment of breakthrough headache attacks, up to 10 doses per month.

06

What researchers measure

Primary outcomes

  1. Change From Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment Phase

    Change from the Observation Phase in the number of monthly migraine days (MMDs) over the 12-week Double-Blind Treatment Phase. Monthly migraine days will be assessed using participant-reported electronic diary data.

    Time frame: 12 Weeks

Secondary outcomes

  1. Percentage of Participants Achieving a ≥50% Reduction From the Observation Phase in Monthly Migraine Days (MMDs) Over the Entire Double-Blind Treatment Phase

    A responder is defined as a participant who achieves a reduction of at least 50% from the Observation Phase in monthly migraine days (MMDs). Monthly migraine days will be determined using participant-reported electronic diary data.

    Time frame: 12 Weeks

  2. Change From Observation Phase in Moderate or Severe Monthly Headache Days Over the Entire Double-Blind Treatment Phase

    Change from the Observation Phase in the number of moderate or severe monthly headache days. Headache intensity will be recorded using participant-reported electronic diary data.

    Time frame: 12 Weeks

  3. Change From Observation Phase in Monthly Acute Migraine Medication Use Days Over the Entire Double-Blind Treatment Phase

    Change from the Observation Phase in the number of monthly acute migraine medication use days. Acute migraine medication use will be captured using participant-reported electronic diary data.

    Time frame: 12 Weeks

  4. Change From Baseline in Migraine-Specific Quality of Life Questionnaire (MSQ) Restrictive Role Function Domain Score

    The Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1 Restrictive Role Function domain assesses limitations in daily social and work-related activities due to migraine. Scores range from 0 to 100, with higher scores indicating better functioning and fewer migraine-related limitations.

    Time frame: Week 12

  5. Change From Observation Phase in Monthly Migraine Days Over the Entire Double-Blind Treatment Phase in Participants With Historical Medication Overuse Headache and Medication Overuse

    Change from the Observation Phase in the number of monthly migraine days among participants with both historical medication overuse headache and medication overuse during the Observation Phase. Monthly migraine days will be determined using participant-reported electronic diary data.

    Time frame: 12 Weeks

  6. Change From Baseline in MSQ Restrictive Role Function Domain Score in Participants With Historical Medication Overuse Headache and Medication Overuse

    The Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1 Restrictive Role Function domain assesses limitations in daily social and work-related activities due to migraine. Scores range from 0 to 100, with higher scores indicating better functioning and fewer migraine-related limitations. This analysis will be performed among participants with both historical medication overuse headache and medication overuse during the Observation Phase.

    Time frame: Week 12

  7. Percentage of Participants Achieving Medication Overuse Headache Remission

    Percentage of participants with both historical medication overuse headache and medication overuse during the Observation Phase who achieve medication overuse headache remission during the Double-Blind Treatment Phase.

    Time frame: 12 Weeks

07

Study locations

18 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2028, 25 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 25 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartActual
Aug 26, 2026
Primary completionEst.
Oct 21, 2028
CompletionEst.
Jan 19, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
17 sites added — first site in Israel. 7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • Papillion Research Center / Avacare · Papillion, United StatesNot yet recruiting→Recruiting
  • Austin Clinical Trial Partners · Austin, United StatesNot yet recruiting→Recruiting
  • Conquest Research-Winter Park · Winter Park, United StatesNot yet recruiting→Recruiting
  • Josephson Wallack Munshower Neurology,PC · Indianapolis, United StatesNot yet recruiting→Recruiting
  • Michigan Headache & Neurological Institute · Ann Arbor, United StatesNot yet recruiting→Recruiting
  • Clinical Neuroscience Solutions, LLC. · Memphis, United StatesNot yet recruiting→Recruiting
  • Shaare Zedek Medical Center · Jerusalem, IsraelNot yet recruiting→Recruiting
Show 17 added (15 United States, 2 Israel)
  • Clinical Endpoints · Scottsdale, United States
  • Neuro-Pain Research Center · Fresno, United States
  • Clinical Research Institute · Los Angeles, United States
  • Conquest Research-Winter Park · Winter Park, United States
  • Josephson Wallack Munshower Neurology,PC · Indianapolis, United States
  • New England Regional Headache Center, Inc. · Worcester, United States
  • Michigan Headache & Neurological Institute · Ann Arbor, United States
  • StudyMetrix Research · City of Saint Peters, United States
  • Hightower Clinical · Oklahoma City, United States
  • Clinical Neuroscience Solutions, LLC. · Memphis, United States
  • FutureSearch Trials of Neurology · Austin, United States
  • FutureSearch Trials of Dallas · Dallas, United States
  • Highland Clinical Research · Salt Lake City, United States
  • Shaare Zedek Medical Center · Jerusalem, Israel
  • Sourasky Medical Center · Tel Aviv, Israel
  • Collective Medical Research · Overland Park, United States
  • Upstate Clinical Research Associates, LLC · Williamsville, United States
across 2 updates, Sep 25, 2026 – Oct 14, 2026
Show all 2 updates
  1. Oct 14, 2026
    2 sites added. 5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Conquest Research-Winter Park · Winter Park, United StatesNot yet recruiting→Recruiting
    • Josephson Wallack Munshower Neurology,PC · Indianapolis, United StatesNot yet recruiting→Recruiting
    • Michigan Headache & Neurological Institute · Ann Arbor, United StatesNot yet recruiting→Recruiting
    • Clinical Neuroscience Solutions, LLC. · Memphis, United StatesNot yet recruiting→Recruiting
    • Shaare Zedek Medical Center · Jerusalem, IsraelNot yet recruiting→Recruiting
    Show 2 added (2 United States)
    • Collective Medical Research · Overland Park, United States
    • Upstate Clinical Research Associates, LLC · Williamsville, United States
    + 1 other change: verification date
  2. Sep 25, 2026
    15 sites added — first site in Israel. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Papillion Research Center / Avacare · Papillion, United StatesNot yet recruiting→Recruiting
    • Austin Clinical Trial Partners · Austin, United StatesNot yet recruiting→Recruiting
    Show 15 added (13 United States, 2 Israel)
    • Clinical Endpoints · Scottsdale, United States
    • Neuro-Pain Research Center · Fresno, United States
    • Clinical Research Institute · Los Angeles, United States
    • Conquest Research-Winter Park · Winter Park, United States
    • Josephson Wallack Munshower Neurology,PC · Indianapolis, United States
    • New England Regional Headache Center, Inc. · Worcester, United States
    • Michigan Headache & Neurological Institute · Ann Arbor, United States
    • StudyMetrix Research · City of Saint Peters, United States
    • Hightower Clinical · Oklahoma City, United States
    • Clinical Neuroscience Solutions, LLC. · Memphis, United States
    • FutureSearch Trials of Neurology · Austin, United States
    • FutureSearch Trials of Dallas · Dallas, United States
    • Highland Clinical Research · Salt Lake City, United States
    • Shaare Zedek Medical Center · Jerusalem, Israel
    • Sourasky Medical Center · Tel Aviv, Israel

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07729462
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 27, 2026
Start date
Aug 26, 2026
Primary completion
Oct 21, 2028 (estimated)
Completion
Jan 19, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimegepant

Start the discussion